Dose‐dependent pharmacokinetics of enprofylline and its renal handling in rats

Masayuki Nadai, Takaaki Hasegawa, Isao Muraoka, Kenzo Takagi, Toshitaka Nabeshima

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The effect of dosage on the pharmacokinetics of the potent bronchodilator enprofylline (3‐propylxanthine; PX) and its renal handling were investigated in rats. Enprofylline (PX) was administered iv in dosages of 2.5, 10, 20, and 40 mg/kg, and PX concentration in plasma and urine was determined by HPLC. The pharmacokinetic parameters were estimated by model‐independent methods. The disappearance of PX from plasma was delayed as dosage was increased. The corresponding pharmacokinetic parameters also showed dose dependency; increases in the volume of distribution (Vd) and mean residence time (MRT) and a decrease in total body clearance (CLT) were observed as dosage was increased from 2.5 to 40 mg/kg. Approximately 80% of the dose, however, was excreted in urine as unchanged PX. Plasma protein binding studies of PX showed concentration dependency and allowed determination of binding parameters, with an apparent dissociation constant (Kd) of 162.50 μM and a binding capacity (nP) of 565.23 μM. Some pharmacokinetic parameters for unbound PX calculated by total plasma concentration and binding parameters also showed dosedependent characteristics. However, no significant change in Vd for unbound PX was observed among administered doses, indicating that the distribution of PX into the body tissues is not changed by an increase in dosage. Renal clearance of unbound PX significantly increased as plasma concentration decreased. The maximum transport capacity (Vmax) and the Michaelis‐Menten constant (Km) for tubular secretion were 60.53 μg/min and 2.27 μg/mL, respectively. The aim of the present study is to demonstrate that both saturable tubular secretion and concentration‐dependent protein binding are responsible for the dose‐dependent pharmacokinetics of PX in rats.

Original languageEnglish
Pages (from-to)648-652
Number of pages5
JournalJournal of Pharmaceutical Sciences
Volume80
Issue number7
DOIs
Publication statusPublished - 01-01-1991
Externally publishedYes

Fingerprint

Pharmacokinetics
Kidney
Protein Binding
Urine
Bronchodilator Agents
Blood Proteins
High Pressure Liquid Chromatography
enprofylline

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Nadai, Masayuki ; Hasegawa, Takaaki ; Muraoka, Isao ; Takagi, Kenzo ; Nabeshima, Toshitaka. / Dose‐dependent pharmacokinetics of enprofylline and its renal handling in rats. In: Journal of Pharmaceutical Sciences. 1991 ; Vol. 80, No. 7. pp. 648-652.
@article{a52b95ccdcf0480a9176ea2999756960,
title = "Dose‐dependent pharmacokinetics of enprofylline and its renal handling in rats",
abstract = "The effect of dosage on the pharmacokinetics of the potent bronchodilator enprofylline (3‐propylxanthine; PX) and its renal handling were investigated in rats. Enprofylline (PX) was administered iv in dosages of 2.5, 10, 20, and 40 mg/kg, and PX concentration in plasma and urine was determined by HPLC. The pharmacokinetic parameters were estimated by model‐independent methods. The disappearance of PX from plasma was delayed as dosage was increased. The corresponding pharmacokinetic parameters also showed dose dependency; increases in the volume of distribution (Vd) and mean residence time (MRT) and a decrease in total body clearance (CLT) were observed as dosage was increased from 2.5 to 40 mg/kg. Approximately 80{\%} of the dose, however, was excreted in urine as unchanged PX. Plasma protein binding studies of PX showed concentration dependency and allowed determination of binding parameters, with an apparent dissociation constant (Kd) of 162.50 μM and a binding capacity (nP) of 565.23 μM. Some pharmacokinetic parameters for unbound PX calculated by total plasma concentration and binding parameters also showed dosedependent characteristics. However, no significant change in Vd for unbound PX was observed among administered doses, indicating that the distribution of PX into the body tissues is not changed by an increase in dosage. Renal clearance of unbound PX significantly increased as plasma concentration decreased. The maximum transport capacity (Vmax) and the Michaelis‐Menten constant (Km) for tubular secretion were 60.53 μg/min and 2.27 μg/mL, respectively. The aim of the present study is to demonstrate that both saturable tubular secretion and concentration‐dependent protein binding are responsible for the dose‐dependent pharmacokinetics of PX in rats.",
author = "Masayuki Nadai and Takaaki Hasegawa and Isao Muraoka and Kenzo Takagi and Toshitaka Nabeshima",
year = "1991",
month = "1",
day = "1",
doi = "10.1002/jps.2600800707",
language = "English",
volume = "80",
pages = "648--652",
journal = "Journal of Pharmaceutical Sciences",
issn = "0022-3549",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

Dose‐dependent pharmacokinetics of enprofylline and its renal handling in rats. / Nadai, Masayuki; Hasegawa, Takaaki; Muraoka, Isao; Takagi, Kenzo; Nabeshima, Toshitaka.

In: Journal of Pharmaceutical Sciences, Vol. 80, No. 7, 01.01.1991, p. 648-652.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Dose‐dependent pharmacokinetics of enprofylline and its renal handling in rats

AU - Nadai, Masayuki

AU - Hasegawa, Takaaki

AU - Muraoka, Isao

AU - Takagi, Kenzo

AU - Nabeshima, Toshitaka

PY - 1991/1/1

Y1 - 1991/1/1

N2 - The effect of dosage on the pharmacokinetics of the potent bronchodilator enprofylline (3‐propylxanthine; PX) and its renal handling were investigated in rats. Enprofylline (PX) was administered iv in dosages of 2.5, 10, 20, and 40 mg/kg, and PX concentration in plasma and urine was determined by HPLC. The pharmacokinetic parameters were estimated by model‐independent methods. The disappearance of PX from plasma was delayed as dosage was increased. The corresponding pharmacokinetic parameters also showed dose dependency; increases in the volume of distribution (Vd) and mean residence time (MRT) and a decrease in total body clearance (CLT) were observed as dosage was increased from 2.5 to 40 mg/kg. Approximately 80% of the dose, however, was excreted in urine as unchanged PX. Plasma protein binding studies of PX showed concentration dependency and allowed determination of binding parameters, with an apparent dissociation constant (Kd) of 162.50 μM and a binding capacity (nP) of 565.23 μM. Some pharmacokinetic parameters for unbound PX calculated by total plasma concentration and binding parameters also showed dosedependent characteristics. However, no significant change in Vd for unbound PX was observed among administered doses, indicating that the distribution of PX into the body tissues is not changed by an increase in dosage. Renal clearance of unbound PX significantly increased as plasma concentration decreased. The maximum transport capacity (Vmax) and the Michaelis‐Menten constant (Km) for tubular secretion were 60.53 μg/min and 2.27 μg/mL, respectively. The aim of the present study is to demonstrate that both saturable tubular secretion and concentration‐dependent protein binding are responsible for the dose‐dependent pharmacokinetics of PX in rats.

AB - The effect of dosage on the pharmacokinetics of the potent bronchodilator enprofylline (3‐propylxanthine; PX) and its renal handling were investigated in rats. Enprofylline (PX) was administered iv in dosages of 2.5, 10, 20, and 40 mg/kg, and PX concentration in plasma and urine was determined by HPLC. The pharmacokinetic parameters were estimated by model‐independent methods. The disappearance of PX from plasma was delayed as dosage was increased. The corresponding pharmacokinetic parameters also showed dose dependency; increases in the volume of distribution (Vd) and mean residence time (MRT) and a decrease in total body clearance (CLT) were observed as dosage was increased from 2.5 to 40 mg/kg. Approximately 80% of the dose, however, was excreted in urine as unchanged PX. Plasma protein binding studies of PX showed concentration dependency and allowed determination of binding parameters, with an apparent dissociation constant (Kd) of 162.50 μM and a binding capacity (nP) of 565.23 μM. Some pharmacokinetic parameters for unbound PX calculated by total plasma concentration and binding parameters also showed dosedependent characteristics. However, no significant change in Vd for unbound PX was observed among administered doses, indicating that the distribution of PX into the body tissues is not changed by an increase in dosage. Renal clearance of unbound PX significantly increased as plasma concentration decreased. The maximum transport capacity (Vmax) and the Michaelis‐Menten constant (Km) for tubular secretion were 60.53 μg/min and 2.27 μg/mL, respectively. The aim of the present study is to demonstrate that both saturable tubular secretion and concentration‐dependent protein binding are responsible for the dose‐dependent pharmacokinetics of PX in rats.

UR - http://www.scopus.com/inward/record.url?scp=0025788569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025788569&partnerID=8YFLogxK

U2 - 10.1002/jps.2600800707

DO - 10.1002/jps.2600800707

M3 - Article

C2 - 1941561

AN - SCOPUS:0025788569

VL - 80

SP - 648

EP - 652

JO - Journal of Pharmaceutical Sciences

JF - Journal of Pharmaceutical Sciences

SN - 0022-3549

IS - 7

ER -